Preplanned initial safety analysis of ACTS-CC 02 trial: A large randomized phase III trial of SOX versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer.
Hiroya Takiuchi
Consultant or Advisory Role - Taiho Pharmaceutical; Takeda
Honoraria - Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical; Takeda
Naohiro Tomita
Honoraria - Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Takeda; Yakult Honsha
Narikazu Boku
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Toshiaki Watanabe
Honoraria - Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Takeda; Yakult Honsha
Kenjiro Kotake
Honoraria - Taiho Pharmaceutical
Michio Itabashi
Honoraria - Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Keiichi Takahashi
Honoraria - Taiho Pharmaceutical; Takeda
Hideo Baba
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Satoshi Morita
Consultant or Advisory Role - Taiho Pharmaceutical; Yakult Honsha
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical
Kenichi Sugihara
Consultant or Advisory Role - Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda (I)
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Yakult Honsha; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda